- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05455385
The Added Value of a Third Supervised Training Session to a Standard 12-week Rehabilitation Program After Breast Cancer: Pilot Study
July 13, 2022 updated by: Universitaire Ziekenhuizen KU Leuven
The Added Value of a Third Supervised Training Session (Ground Exercises or Hydrotherapy) to a Standard 12-week Rehabilitation Program After Breast Cancer: Pilot Study
Breast cancer is the most common type of cancer diagnosed in women.
A good rehabilitation program is essential for a good recovery after breast cancer, both physically and mentally.
The aim of this study is to determine if there is an added value of a third supervised training session within a standard 12-week rehabilitation program to improve physical and mental functioning after breast cancer.
The investigators also want to determine the added value of hydrotherapy as a third training session within a 12-week rehabilitation program compared to a third training session with ground exercises to improve physical and mental functioning after breast cancer.
Study Overview
Status
Completed
Conditions
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Leuven, Belgium, 3000
- University Hospital Leuven
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- men and women after surgery for breast cancer (mastectomy/breast-conserving and/or axillary gland resection/sentinel biopsy)
- possible (neo)adjuvant chemotherapy and radiotherapy have been completed
- hormone and/or immunotherapy may still be ongoing
Exclusion Criteria:
- comorbidities that make hydrotherapy impossible, i.e. open wounds or allergy to chlorine
- oncological unstable disease
- terminal patients
- severe physical disabilities
- severe mental disabilities
- pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Control group
|
The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
|
Experimental: Hydrotherapy group
|
The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
The hydrotherapy group receives 1.5h additional hydrotherapy/week in addition to the standard program.
|
Experimental: Ground exercise group
|
The standard program consisted of 1 session in the fitness room and 1 session in the sports hall/week during 12 weeks.
The ground exercise group, receives 1.5h ground exercises/week in addition to the standard program.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Shoulder mobility
Time Frame: 12 weeks
|
Shoulder Range of Motion (ROM) is measured with a Dr. Rippstein Plurimeter-V analogue inclinometer
|
12 weeks
|
Arm volume
Time Frame: 12 weeks
|
Arm circumference measurements are performed bilaterally using a perimeter, a flexible stainless-steel rod with a measuring tape attached every 4 cm and a 20 g weight at the end.Arm circumference is measured at the level of the olecranon and at 4, 8, 12, 16 and 20 cm proximal and distal to the olecranon.
The volume of the arm is calculated using a formula.
The relatively excessive arm volume is then calculated as follows: (volume of operated limb - volume of non-operated limb) / volume of non-operated limb) x 100.
|
12 weeks
|
Force based on handgrip strength
Time Frame: 12 weeks
|
Handgrip strength is measured with the Jamar Handheld Dynamometer
|
12 weeks
|
Flexibility by means of the sit-and-reach test
Time Frame: 12 weeks
|
The Sit and reach test is one of the linear flexibility tests which helps to measure the extensibility of the hamstrings and lower back.
|
12 weeks
|
Exercise capacity based on 6-minute walk test
Time Frame: 12 weeks
|
The 6-minute walk test is used to assess patients' gait pattern, walking speed and cardiorespiratory endurance.
It measures the maximum distance the patient can comfortably cover in 6 minutes.
|
12 weeks
|
Body image using the Body Image Scale
Time Frame: 12 weeks
|
The BIS is a patient-reported outcome measure to evaluate the body image during and after cancer treatment.
The BIS consists of 10 items and measures cognitive, affective and behavioral symptoms of body image.
It uses a 4-point scale, where 0 = not at all and 3 = very much.
The total score ranges from 0 to 30 and can be calculated by adding the 10 items together.
The higher the score, the higher the level of body image disturbance.
|
12 weeks
|
self-reported pain using the Brief Pain Inventory
Time Frame: 12 weeks
|
The BPI measures the severity of pain symptoms and interference with daily functioning using an 11-point scale.
It has 4 questions for pain (worst pain, least pain, average pain and pain right now) and 7 for pain-related functioning (general physical activity, mood, ability to walk, work and household tasks, relationships with others, sleep, vitality).
The total score is calculated by averaging all the different questions.
A higher score indicates a higher barrier
|
12 weeks
|
Fatigue using the Functional Assessment of Chronic Illness Therapy - Fatigue Scale
Time Frame: 12 weeks
|
FACIT-F scale measures the impact of fatigue caused by the treatment of chronic diseases.
It consists of 13 items, with a score between 13 and 65.
A higher score on the scale indicates more fatigue
|
12 weeks
|
Anxiety and depression using the Hospital Anxiety and Depression Scale
Time Frame: 12 weeks
|
The HADS measures core symptoms of anxiety and depression without including physical symptoms.
It is a short questionnaire that is easy to use.
It consists of an anxiety scale and a depression scale, both containing 7 items with a total score from 0-21 where the higher the score, the more complaints.
A score higher than 8 can be an indication for a psychiatric condition
|
12 weeks
|
Quality of life using the McGill Quality Of Life questionnaire
Time Frame: 12 weeks
|
The McGill Quality of Life Questionnaire measures multiple dimensions and overall quality of life of people with a life-threatening illness.
It measures quality of life according to 5 domains: physical symptoms, physical well-being, psychological, existential and support.
A scale of 0-10 is used for each question with anchors at each end.
The scores consist of three parts: (1) Part "A" is a Single-Item Scale (MQOL-SIS) that measures overall quality of life, (2) five subscales discussed above, and (3) a total score that is the average of the five subscales.
Before calculating the MQOL scores, the scores for items 1, 2, 3, 5, 6, 7, and 8 must be converted by subtracting the raw score for each item from 10.
For the results we only look at the third part, namely the total score.
A higher score means a better quality of life
|
12 weeks
|
Physical functioning using the Patient-Reported Outcomes Measurement Information System
Time Frame: 12 weeks
|
The PROMIS-PF includes many questionnaires in the areas of physical, mental and social health that can be used in the general population and in individuals suffering from chronic conditions.
In our study we use the PROMIS for Physical Functioning, which is a 5-point scale where 1 = effortless and 10 = impossible.
The score range goes from 10 to 50.
A higher PROMIS score represents more of the concept being measured.
So the higher the score, the better the physical functioning
|
12 weeks
|
Patient Specific Complaints
Time Frame: 12 weeks
|
The PSC can be used to gain insight into the activities that a patient has difficulty with because of his/her symptoms.
The patient is asked to name three activities in which he/she experiences discomfort in daily life or has difficulty with because of his/her symptoms or condition, and that he/she would like to improve with the therapy.
The selected activities are scored on the amount of effort it takes him/her to perform this activity on an 11-point scale, where 0 = no effort at all and 10 = impossible.
The total score is calculated by averaging the three individual scores.
The higher the score, the more problems are experienced in performing the actions
|
12 weeks
|
Global Perceived Effect
Time Frame: 12 weeks
|
The GPE can be used to measure the patient's opinion of recovery.
The GPE consists of 2 items that must be answered on a 7-point scale.
The scale runs from fully recovered to worse than ever.
The first item is about "To what extent have you recovered from your complaints since the start of the treatment?"
where 7 = worse than ever and 0 = completely improved.
The second item is about "How satisfied are you with your treatment?".
This scale goes from 7 = absolutely dissatisfied and 0 = absolutely satisfied
|
12 weeks
|
Attendance: number of times the participant was present
Time Frame: 12 weeks
|
By attendance we mean the number of times the participant was present during the rehabilitation.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: An De Groef, Prof, KU Leuven
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 5, 2021
Primary Completion (Actual)
January 31, 2022
Study Completion (Actual)
January 31, 2022
Study Registration Dates
First Submitted
July 7, 2022
First Submitted That Met QC Criteria
July 7, 2022
First Posted (Actual)
July 13, 2022
Study Record Updates
Last Update Posted (Actual)
July 14, 2022
Last Update Submitted That Met QC Criteria
July 13, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- s63338
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on standard 12-week rehabilitation program
-
Beth Israel Deaconess Medical CenterNational Center for Complementary and Integrative Health (NCCIH)Completed
-
University of ManitobaCompleted
-
VA Office of Research and DevelopmentNot yet recruitingDiabetic Foot UlcerUnited States
-
Chinese University of Hong KongCompletedEvaluation of Energy Expenditure and Cardiovascular Health Effects From Tai Chi and Walking ExercisePhysical ActivityHong Kong
-
Wake Forest University Health SciencesActive, not recruiting
-
The Hong Kong Polytechnic UniversityCompletedTotal Knee ArthroplastyHong Kong
-
KU LeuvenCompletedQuality of Life | Sleep | Well-being | Motivation | Social Support | Leadership | Functional Ability | Social IdentityBelgium
-
University of ManitobaJuvenile Diabetes Research Foundation; Canadian Institutes of Health Research...Not yet recruitingPhysical Activity | Type 1 Diabetes
-
University GhentCompletedHamstring InjuryBelgium
-
KU LeuvenCompletedLeadership | Empowerment | IdentificationBelgium